医学
大流行
恶化
肺炎
奥司他韦
重症监护医学
扎那米韦
人口
临床试验
病毒性肺炎
神经氨酸酶
儿科
重叠感染
内科学
疾病
免疫学
2019年冠状病毒病(COVID-19)
病毒
传染病(医学专业)
环境卫生
作者
Nelson Lee,Michael G. Ison
出处
期刊:Antiviral Therapy
[International Medical Press]
日期:2012-01-01
卷期号:17 (1 Pt B): 143-157
被引量:57
摘要
Annual influenza epidemics and periodic pandemics result in excess hospital admissions. Hospitalization typically occurs in those with underlying medical conditions, those at the extremes of age and in pregnant woman; young adults and obese individuals were also at increased risk during the 2009 H1N1 pandemic. Severe influenza pneumonia, exacerbation of underlying lung diseases, cardiovascular and cerebrovascular events and bacterial superinfection are common reasons for hospitalization. Clinical diagnosis is unreliable and virological confirmation can be challenging. Overall mortality among adults hospitalized with influenza ranges from 4% to 8%, although higher mortality (>10-15%) may be seen during pandemics and among the immunocompromised. Recent data have suggested that neuraminidase inhibitors, particularly when given early, can accelerate viral clearance and improve clinical outcomes in hospitalized adults; thus, antiviral treatment should be considered in all cases. Controlled clinical trials are urgently needed in this population to evaluate comparative treatment efficacy of different agents and combinations, including emergence of antiviral resistance, and to address issues related to dosage, duration and parenteral route.
科研通智能强力驱动
Strongly Powered by AbleSci AI